[1]曾碧雨,姚 春,陈月桥,等.中医药治疗乙型肝炎肝硬化失代偿期研究进展[J].陕西中医,2024,(6):850-854.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.028]
　ZENG Biyu,YAO Chun,CHEN Yueqiao,et al.New progress on the treatment of hepatitis B cirrhosis in the decompensated stage with traditional Chinese medicine[J].,2024,(6):850-854.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.028]
点击复制

中医药治疗乙型肝炎肝硬化失代偿期研究进展
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年6期
页码:
850-854
栏目:
综 述
出版日期:
2024-06-05

文章信息/Info

Title:
New progress on the treatment of hepatitis B cirrhosis in the decompensated stage with traditional Chinese medicine
作者:
曾碧雨1; 姚 春1; 陈月桥2; 罗 琪1; 张 荣1; 莫宏英1; 周洁清1
(1.广西中医药大学研究生院,广西 南宁 530200; 2.广西中医药大学第一附属医院肝病科,广西 南宁 530001)
Author(s):
ZENG Biyu; YAO Chun; CHEN Yueqiao; LUO Qi; ZHANG Rong; MO Hongying; ZHOU Jieqing
(Graduate School,Guangxi University of Chinese Medicine,Nanning 530200,China)
关键词:
乙型肝炎肝硬化;  失代偿期;  中医内治;  中医外治;  病因病机
Keywords:
Hepatitis B cirrhosis;  Decompensated stage;  Traditional Chinese medicine internal treatment;  Traditional Chinese medicine external treatment;  Etiology and pathogenesis
分类号:
R 657.31
DOI:
DOI:10.3969/j.issn.1000-7369.2024.06.028
文献标志码:
A
摘要:
乙型肝炎病毒感染是肝硬化发生的最主要原因,疾病发展至失代偿期时患者的生存率极低,是肝病患者死亡的主要原因之一。目前临床上单纯的西医治疗未能提高整体疗效,而中医药对乙型肝炎肝硬化失代偿期的防治逐渐展现出显著优势,其临床经验丰富,且不良反应少,有效改善患者的症状和提高生活质量。基于此,通过查阅国内外相关文献,结合古今学者对乙型肝炎肝硬化失代偿期的认识,归纳分析乙型肝炎肝硬化失代偿期的病理生理过程、病因病机、中医辨证论治及中医内治和外治的防治理念,为进一步推动乙型肝炎肝硬化失代偿期的中医药治疗提供参考及新思路。
Abstract:
Hepatitis B virus infection is the main cause of liver cirrhosis,and the survival rate of patients is extremely low when the disease develops to the decompensated stage,which is one of the main causes of death of liver disease patients.At present,purely western medical treatment fails to improve the overall efficacy,and traditional Chinese medicine(TCM)has gradually demonstrated its significant advantages in the prevention and treatment of hepatitis B cirrhosis in the decompensated stage,which is rich in clinical experience and has fewer adverse reactions,and effectively improves the symptoms and quality of life of the patients.Based on this,by reviewing the relevant literature at home and abroad,combining the knowledge of ancient and modern scholars on the decompensated stage of hepatitis B cirrhosis,we summarized and analyzed the pathophysiological process,etiology and pathogenesis of the decompensated stage of hepatitis B cirrhosis,Chinese medicine diagnosis and treatment,as well as Chinese medicine concepts for prevention and control of internal and external treatment,with the aim of providing references and new ideas for the further promotion of the treatment of hepatitis B cirrhosis in the decompensated stage of traditional Chinese medicine.

参考文献/References:

[1] 徐小元,丁惠国,李文刚,等.肝硬化诊治指南[J].临床肝胆病杂志,2019,35(11):2408-2425.
[2] HUANG D Q,TERRAULT N A,TACKE F,et al.Global epidemiology of cirrhosis-aetiology,trends and predictions[J].Nature Reviews Gastroenterology & Hepatology,2023,20(6):388-398.
[3] CHEN F,YAO Y,LI Z,et al.Assessment of compensated advanced chronic liver disease based on serum bile acids in chronic hepatitis B patients[J].Scientific Reports,2023,13(1):12834.
[4] 田艳茹.miR-133b与慢性乙型肝炎肝纤维化相关性研究[J].陕西医学杂志,2023,52(4):448-451.
[5] 陈洁,袁星,余先祥.乙肝、艾滋病病毒的发病机制和干预措施的比较[J].临床医药文献电子杂志,2019,6(12):191-194.
[6] SCHWARZ M,SCHWARZ C,BURGHART L,et al.Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomes[J].PLoS One,2023,18(8):290352.
[7] KUMAR R,KUMAR S,PRAKASH S S.Compensated liver cirrhosis:Natural course and disease-modifying strategies[J].World Journal of Methodology,2023,13(4):179.
[8] MAO T,ZHANG B,YANG T,et al.Evaluation of five lymphocyte-based scores for prediction of mortality in hepatitis B virus-associated decompensated cirrhosis[J].Heliyon,2023,9(8):18556.
[9] AIROLA C,PALLOZZI M,CERRITO L,et al.Microvascular thrombosis and liver fibrosis progression:Mechanisms and clinical applications[J].Cells,2023,12(13):1712.
[10] 曹敬,梁潇浪,张兰,等.影响乙型肝炎肝硬化失代偿期预后的相关因素分析[J].实用医院临床杂志,2020,17(1):171-174.
[11] 赖俐伶,刘华宝,李梅,等.健脾补肾法改善肝硬化失代偿期患者营养状况证治探讨[J].实用中医药杂志,2021,37(11):1955-1957.
[12] 李琼,滕龙,李永勤,等.周信有辨治病毒性肝硬化经验[J].中医杂志,2018,59(8):643-645.
[13] 朱艳华,节阳华,张立平.疏肝理气养血汤加减治疗癌因性疲乏疗效研究[J].陕西中医,2023,44(11):1550-1553.
[14] 孟祥林,李海雷,罗宏伟.肝病实脾理论指导下中药干预失代偿期肝硬化营养状态的疗效分析[J].中医临床研究,2016,8(4):16-17.
[15] 刘巍,韩涛.血府逐瘀汤加减对乙肝肝硬化失代偿期肝纤维化及炎性因子的影响[J].实用药物与临床,2021,24(9):821-825.
[16] 郝慧敏,魏晓广,高春献.血府逐瘀汤加减联合恩替卡韦对乙肝肝硬化失代偿期肝纤维化的影响[J].检验医学与临床,2023,20(8):1107-1111.
[17] 陈颖琪,徐玉萍,孙学华.温阳健脾方联合西医常规疗法治疗乙型肝炎肝硬化失代偿期患者的研究[J].中西医结合肝病杂志,2021,31(8):715-717.
[18] 李国焕,张铭业,唐云云.温阳益气汤治疗老年失代偿期乙肝后肝硬化患者的效果[J].中国当代医药,2019,26(26):160-163.
[19] 陈镇清,赵有为,赖清谊,等.扶正活血解毒汤联合恩替卡韦治疗乙肝肝硬化失代偿期临床观察[J].光明中医,2019,34(5):774-776.
[20] 张宇,柯华菁,吴刚.健脾疏肝汤加减联合恩替卡韦治疗乙肝肝硬化失代偿期的效果[J].中国当代医药,2020,27(36):67-69,73.
[21] 吕黄华.壮肝逐瘀煎联合恩替卡韦治疗正虚瘀结型乙肝肝硬化失代偿期的临床观察[D].南宁:广西中医药大学,2021.
[22] 李小蕃.柔肝化纤颗粒对乙肝肝硬化失代偿期(肝肾阴虚证)的临床研究[D].南宁:广西中医药大学,2020.
[23] 胡萍,徐淑兰,宋冬梅,等.探讨柔肝化纤颗粒联合核苷类抗病毒药物对乙型肝炎后肝硬化失代偿期患者肝功能及门静脉系统血流动力学的影响[J].中国处方药,2023,21(3):107-110.
[24] 许海芹.益气解毒通络法治疗乙肝肝硬化失代偿期临床疗效的回顾性研究[D].北京:北京中医药大学,2021.
[25] 冯志刚,李涛,赵冰清,等.复方鳖甲软肝片联合恩替卡韦对乙肝肝硬化失代偿期患者疗效、肝功能、免疫功能影响研究[J].中华中医药学刊,2022,40(1):184-187.
[26] 马婧婧,高洁,张丽红.扶正化瘀胶囊联合恩替卡韦治疗对HBV肝硬化失代偿期患者肝肾功能的影响[J].中西医结合肝病杂志,2022,32(5):423-425.
[27] 闵捷.地五养肝胶囊辅助治疗乙肝肝硬化失代偿期疗效分析[J].江西医药,2019,54(12):1581-1583.
[28] 周红.肝爽颗粒联合恩替卡韦分散片治疗失代偿期乙型肝炎肝硬化的临床效果[J].现代中医药,2019,39(4):66-68.
[29] 李媛,龙富立,张衎,等.健肝颗粒治疗乙型病毒性肝炎肝硬化的临床疗效观察[J].中华中医药杂志,2021,36(8):5109-5112.
[30] 原景,杜韩,万梅绪,等.丹参有效成分及丹参类制剂抗炎药理作用的研究进展[J].药物评价研究,2021,44(11):2322-2332.
[31] 魏小敏,王丽丽,刘海霞,等.丹参素通过STAT3/JAK2/SOCS1信号通路在妊娠期糖尿病干预中的作用机制研究[J].陕西医学杂志,2023,52(5):508-512.
[32] 侯艾林,贺汉军,唐剑萍.复方丹参注射液联合替诺福韦酯治疗对乙肝肝硬化失代偿期肝脏硬度及血清Th1/Th2型细胞因子表达的影响[J].中华中医药学刊,2022,40(11):69-72.
[33] 吕奕,王毓麟.参麦注射液联合阿德福韦酯治疗乙肝肝硬化失代偿期的疗效[J].医学信息,2020,33(6):162-163.
[34] 李志英,李宏韬,刘申颖,等.丹红注射液联合异甘草酸镁对乙型肝炎肝硬化失代偿期患者的临床疗效及对肝功能、肝纤维化的影响[J].中国医学创新,2019,16(30):1-4.
[35] 萧焕明,施梅姐,谢玉宝,等.肝病中医外治法的临床应用思考[J].中医杂志,2020,61(16):1460-1462.
[36] 王鲁扬,刘源香.中医外治法治疗偏头痛疗效Meta分析[J].陕西中医,2023,44(11):1640-1645.
[37] 许钰波.针刺对肝硬化门静脉高压临床疗效研究[J].世界中医药,2017,12(1):152-156,160.
[38] 韦群燕.三黄汤保留灌肠治疗肝硬化失代偿期临床疗效观察[J].内蒙古中医药,2019,38(7):71-72.
[39] 陈舒婷,胡甜,彭莉.复方大黄煎剂保留灌肠治疗肝硬化肝性脑病临床观察[J].光明中医,2022,37(13):2298-2301.
[40] 符燕青.柔肝化纤颗粒联合穴位敷贴治疗乙肝肝硬化腹水疗效观察[D].南宁:广西中医药大学,2022.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(82260899); 广西壮族自治区重点研发项目(桂科AB22035076); 国家中医药管理局高水平中医药重点学科建设项目(2023027-01); 广西中医药大学“桂派中医药传承创新团队”建设项目(2022A001)
更新日期/Last Update: 2024-06-11